An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer
- PMID: 19638211
- PMCID: PMC2750116
- DOI: 10.1186/bcr2344
An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer
Erratum in
- Breast Cancer Res. 2011;13(4):406
Abstract
Introduction: Perhaps the major challenge in developing more effective therapeutic strategies for the treatment of breast cancer patients is confronting the heterogeneity of the disease, recognizing that breast cancer is not one disease but multiple disorders with distinct underlying mechanisms. Gene-expression profiling studies have been used to dissect this complexity, and our previous studies identified a series of intrinsic subtypes of breast cancer that define distinct populations of patients with respect to survival. Additional work has also used signatures of oncogenic pathway deregulation to dissect breast cancer heterogeneity as well as to suggest therapeutic opportunities linked to pathway activation.
Methods: We used genomic analyses to identify relations between breast cancer subtypes, pathway deregulation, and drug sensitivity. For these studies, we use three independent breast cancer gene-expression data sets to measure an individual tumor phenotype. Correlation between pathway status and subtype are examined and linked to predictions for response to conventional chemotherapies.
Results: We reveal patterns of pathway activation characteristic of each molecular breast cancer subtype, including within the more aggressive subtypes in which novel therapeutic opportunities are critically needed. Whereas some oncogenic pathways have high correlations to breast cancer subtype (RAS, CTNNB1, p53, HER1), others have high variability of activity within a specific subtype (MYC, E2F3, SRC), reflecting biology independent of common clinical factors. Additionally, we combined these analyses with predictions of sensitivity to commonly used cytotoxic chemotherapies to provide additional opportunities for therapeutics specific to the intrinsic subtype that might be better aligned with the characteristics of the individual patient.
Conclusions: Genomic analyses can be used to dissect the heterogeneity of breast cancer. We use an integrated analysis of breast cancer that combines independent methods of genomic analyses to highlight the complexity of signaling pathways underlying different breast cancer phenotypes and to identify optimal therapeutic opportunities.
Figures





Similar articles
-
Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics.Breast Cancer Res. 2010;12(3):R42. doi: 10.1186/bcr2596. Epub 2010 Jun 24. Breast Cancer Res. 2010. PMID: 20576095 Free PMC article.
-
Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomas.Breast Cancer Res. 2016 Apr 1;18(1):39. doi: 10.1186/s13058-016-0696-2. Breast Cancer Res. 2016. PMID: 27036195 Free PMC article.
-
Effective personalized therapy for breast cancer based on predictions of cell signaling pathway activation from gene expression analysis.Oncogene. 2017 Jun 22;36(25):3553-3561. doi: 10.1038/onc.2016.503. Epub 2017 Jan 30. Oncogene. 2017. PMID: 28135251
-
Functional genomic analysis of drug sensitivity pathways to guide adjuvant strategies in breast cancer.Breast Cancer Res. 2008;10(5):214. doi: 10.1186/bcr2159. Epub 2008 Oct 31. Breast Cancer Res. 2008. PMID: 18986507 Free PMC article. Review.
-
Molecular biology of breast cancer.Clin Transl Oncol. 2006 Jan;8(1):7-14. doi: 10.1007/s12094-006-0089-6. Clin Transl Oncol. 2006. PMID: 16632434 Review.
Cited by
-
A prognostic signature of defective p53-dependent G1 checkpoint function in melanoma cell lines.Pigment Cell Melanoma Res. 2012 Jul;25(4):514-26. doi: 10.1111/j.1755-148X.2012.01010.x. Epub 2012 Jun 1. Pigment Cell Melanoma Res. 2012. PMID: 22540896 Free PMC article.
-
Pumilio facilitates miRNA regulation of the E2F3 oncogene.Genes Dev. 2012 Feb 15;26(4):356-68. doi: 10.1101/gad.182568.111. Genes Dev. 2012. PMID: 22345517 Free PMC article.
-
A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis.Lancet Oncol. 2011 Apr;12(4):377-86. doi: 10.1016/S1470-2045(11)70044-4. Epub 2011 Mar 22. Lancet Oncol. 2011. PMID: 21435948 Free PMC article.
-
Recent Advances in Integrative Multi-Omics Research in Breast and Ovarian Cancer.J Pers Med. 2021 Feb 19;11(2):149. doi: 10.3390/jpm11020149. J Pers Med. 2021. PMID: 33669749 Free PMC article. Review.
-
Assessment of kidney organ quality and prediction of outcome at time of transplantation.Semin Immunopathol. 2011 Mar;33(2):185-99. doi: 10.1007/s00281-011-0248-x. Epub 2011 Jan 28. Semin Immunopathol. 2011. PMID: 21274534 Review.
References
-
- Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning PE, Brown PO, Borresen-Dale AL, Botstein D. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100:8418–8423. doi: 10.1073/pnas.0932692100. - DOI - PMC - PubMed
-
- Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L, Nobel A, Parker J, Ewend MG, Sawyer LR, Wu J, Liu Y, Nanda R, Tretiakova M, Ruiz Orrico A, Dreher D, Palazzo JP, Perreard L, Nelson E, Mone M, Hansen H, Mullins M, Quackenbush JF, Ellis MJ, Olopade OI, Bernard PS, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics. 2006;7:96. doi: 10.1186/1471-2164-7-96. - DOI - PMC - PubMed
-
- Black EP, Huang E, Dressman H, Rempel R, Laakso N, Asa SL, Ishida S, West M, Nevins JR. Distinct gene expression phenotypes of cells lacking Rb and Rb family members. Cancer Res. 2003;63:3716–3723. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous